Vedolizumab

A recent study showed that Entyvio remained effective 2 years after patients with inflammatory bowel disease reduced their dosing frequency from every 4 weeks to every 8 weeks. It was the top story in gastroenterology last week.

Patients with inflammatory bowel disease who reduced the frequency of Entyvio dosing showed high persistence and low rates of relapse, according to study results.

A recent study showed that Entyvio was associated with higher rates of ulcerative colitis remission than anti-TNF agents. It was the top story in gastroenterology last week.

Patients with ulcerative colitis who received Entyvio in routine practice experienced higher rates of remission than those treated with anti-TNF agents, according to study results.

Patient preference favoring treatment discontinuation was improved during treatment with Entyvio or Stelara compared with anti-TNF therapy in patients with inflammatory bowel disease, according to study results.

Adverse pregnancy outcomes among women with inflammatory bowel disease on biologic therapy were comparable to that of the general population, according to study results.

Long-term data from the GEMINI trial showed that Entyvio maintained its favorable safety profile in patients with inflammatory bowel disease over 8 years. It was the top story in gastroenterology last week.

Remicade and Entyvio were effective for the treatment of patients with checkpoint inhibitor-induced enterocolitis, according to the results of a meta-analysis.

Patients who received Entyvio or Stelara for inflammatory bowel disease who had more comorbidities were at increased risk for hospitalization and infection, according to research published in Alimentary Pharmacology & Therapeutics.

The safety profile of Entyvio remained favorable through 8 years of use in patients with inflammatory bowel disease, according to results from the GEMINI long-term safety study.